384 related articles for article (PubMed ID: 34975873)
21. Neoadjuvant Immunotherapy Leads to Major Response and Low Recurrence in Localized Mismatch Repair-Deficient Colorectal Cancer.
Xiao BY; Zhang X; Cao TY; Li DD; Jiang W; Kong LH; Tang JH; Han K; Zhang CZ; Mei WJ; Xiao J; Pan ZZ; Li YF; Zhang XS; Ding PR
J Natl Compr Canc Netw; 2023 Jan; 21(1):60-66.e5. PubMed ID: 36630898
[TBL] [Abstract][Full Text] [Related]
22. A TGFβ-Dependent Stromal Subset Underlies Immune Checkpoint Inhibitor Efficacy in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Colorectal Cancer.
Endo E; Okayama H; Saito K; Nakajima S; Yamada L; Ujiie D; Kase K; Fujita S; Endo H; Sakamoto W; Saito M; Saze Z; Momma T; Ohki S; Mimura K; Kono K
Mol Cancer Res; 2020 Sep; 18(9):1402-1413. PubMed ID: 32493700
[TBL] [Abstract][Full Text] [Related]
23. Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapy.
Geurts BS; Zeverijn LJ; van Berge Henegouwen JM; van der Wijngaart H; Hoes LR; de Wit GF; Spiekman IA; Battaglia TW; van Beek DM; Roepman P; Jansen AM; de Leng WW; Broeks A; Labots M; van Herpen CM; Gelderblom H; Verheul HM; Snaebjornsson P; Voest EE
J Pathol; 2024 Jul; 263(3):288-299. PubMed ID: 38747304
[TBL] [Abstract][Full Text] [Related]
24. Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers.
Fucà G; Cohen R; Lonardi S; Shitara K; Elez ME; Fakih M; Chao J; Klempner SJ; Emmett M; Jayachandran P; Bergamo F; García MD; Mazzoli G; Provenzano L; Colle R; Svrcek M; Ambrosini M; Randon G; Shah AT; Salati M; Fenocchio E; Salvatore L; Chida K; Kawazoe A; Conca V; Curigliano G; Corti F; Cremolini C; Overman M; Andre T; Pietrantonio F
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35110358
[TBL] [Abstract][Full Text] [Related]
25. Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain.
Garcia-Carbonero R; González Astorga B; Vidal Tocino R; Contreras Toledo D; Pericay C; Fernández Montes A; Falcó E; González Cordero M; Reina Zoilo JJ; Alonso V; Rodríguez Salas N; Gil-Raga M; Santos C; Páez D; Anton-Pascual B; Aguilar F; Morales P
Clin Transl Oncol; 2024 Apr; 26(4):864-871. PubMed ID: 37651021
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of PD-1 Inhibitor Combined with Bevacizumab in Treatment of Advanced Endometrial Cancer Patients with Mismatch Repair Deficiency (dMMR)/High-Level Microsatellite Instability (MSI-H).
Liao Y; Zhu C; Song X; Ruan J; Ding Y; Chen Y; Yang Q
Med Sci Monit; 2022 Mar; 28():e934493. PubMed ID: 35322001
[TBL] [Abstract][Full Text] [Related]
27. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
[TBL] [Abstract][Full Text] [Related]
28. A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy.
Élez E; Mulet-Margalef N; Sanso M; Ruiz-Pace F; Mancuso FM; Comas R; Ros J; Argilés G; Martini G; Sanz-Garcia E; Baraibar I; Salvà F; Noguerido A; Cuadra-Urteaga JL; Fasani R; Garcia A; Jimenez J; Aguilar S; Landolfi S; Hernández-Losa J; Braña I; Nuciforo P; Dienstmann R; Tabernero J; Salazar R; Vivancos A
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613564
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trial.
Coutzac C; Bibeau F; Ben Abdelghani M; Aparicio T; Cohen R; Coquan E; Dubreuil O; Evesque L; Ghiringhelli F; Kim S; Lesourd S; Neuzillet C; Phelip JM; Piessen G; Rochigneux P; Samalin E; Soularue E; Touchefeu Y; Tougeron D; Zaanan A; de la Fouchardière C
Dig Liver Dis; 2022 Oct; 54(10):1335-1341. PubMed ID: 35907691
[TBL] [Abstract][Full Text] [Related]
30. Heterogeneity of Mismatch Repair Status and Microsatellite Instability between Primary Tumour and Metastasis and Its Implications for Immunotherapy in Colorectal Cancers.
Evrard C; Messina S; Sefrioui D; Frouin É; Auriault ML; Chautard R; Zaanan A; Jaffrelot M; De La Fouchardière C; Aparicio T; Coriat R; Godet J; Silvain C; Randrian V; Sabourin JC; Guimbaud R; Miquelestorena-Standley E; Lecomte T; Moulin V; Karayan-Tapon L; Tachon G; Tougeron D
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457245
[TBL] [Abstract][Full Text] [Related]
31. Comparative analysis of microsatellite instability by next-generation sequencing, MSI PCR and MMR immunohistochemistry in 1942 solid cancers.
Kang SY; Kim DG; Ahn S; Ha SY; Jang KT; Kim KM
Pathol Res Pract; 2022 May; 233():153874. PubMed ID: 35405622
[TBL] [Abstract][Full Text] [Related]
32. Clinical-Grade Detection of Microsatellite Instability in Colorectal Tumors by Deep Learning.
Echle A; Grabsch HI; Quirke P; van den Brandt PA; West NP; Hutchins GGA; Heij LR; Tan X; Richman SD; Krause J; Alwers E; Jenniskens J; Offermans K; Gray R; Brenner H; Chang-Claude J; Trautwein C; Pearson AT; Boor P; Luedde T; Gaisa NT; Hoffmeister M; Kather JN
Gastroenterology; 2020 Oct; 159(4):1406-1416.e11. PubMed ID: 32562722
[TBL] [Abstract][Full Text] [Related]
33. Tumor-agnostic drug development in dMMR/MSI-H solid tumors.
Bhamidipati D; Subbiah V
Trends Cancer; 2023 Oct; 9(10):828-839. PubMed ID: 37517955
[TBL] [Abstract][Full Text] [Related]
34. Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer.
Pecci F; Cantini L; Bittoni A; Lenci E; Lupi A; Crocetti S; Giglio E; Giampieri R; Berardi R
Curr Treat Options Oncol; 2021 Jun; 22(8):69. PubMed ID: 34110510
[TBL] [Abstract][Full Text] [Related]
35. Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer.
Colle R; Radzik A; Cohen R; Pellat A; Lopez-Tabada D; Cachanado M; Duval A; Svrcek M; Menu Y; André T
Eur J Cancer; 2021 Feb; 144():9-16. PubMed ID: 33316636
[TBL] [Abstract][Full Text] [Related]
36. Dickkopf 1 impairs the tumor response to PD-1 blockade by inactivating CD8+ T cells in deficient mismatch repair colorectal cancer.
Sui Q; Liu D; Jiang W; Tang J; Kong L; Han K; Liao L; Li Y; Ou Q; Xiao B; Liu G; Ling Y; Chen J; Liu Z; Zuo Z; Pan Z; Zhou P; Zheng J; Ding PR
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33782107
[TBL] [Abstract][Full Text] [Related]
37. B2M and JAK1/2-mutated MSI-H Colorectal Carcinomas Can Benefit From Anti-PD-1 Therapy.
Zhang C; Li D; Xiao B; Zhou C; Jiang W; Tang J; Li Y; Zhang R; Han K; Hou Z; Zhang L; Sui Q; Liao L; Pan Z; Zhang X; Ding P
J Immunother; 2022 May; 45(4):187-193. PubMed ID: 35343934
[TBL] [Abstract][Full Text] [Related]
38. Microsatellite Stable Colorectal Cancer With an Immunogenic Phenotype: Challenges in Diagnosis and Treatment.
Saller J; Qin D; Felder S; Coppola D
Clin Colorectal Cancer; 2020 Jun; 19(2):123-131. PubMed ID: 32171644
[TBL] [Abstract][Full Text] [Related]
39. Clinical benefits of PD-1/PD-L1 inhibitors in patients with metastatic colorectal cancer: a systematic review and meta-analysis.
Zhang X; Yang Z; An Y; Liu Y; Wei Q; Xu F; Yao H; Zhang Z
World J Surg Oncol; 2022 Mar; 20(1):93. PubMed ID: 35331250
[TBL] [Abstract][Full Text] [Related]
40. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]